Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New liquid biopsy could replace needle biopsies for prostate cancer

NCT ID NCT05141383

Diagnosis Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study collected urine and blood samples from 80 men, including those with prostate cancer, suspected cancer, or benign prostate enlargement, as well as healthy donors. The goal was to find RNA biomarkers that could lead to a simple liquid biopsy test for diagnosing and monitoring prostate cancer. Researchers are analyzing the samples to see if they can reliably detect cancer without invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could lead to a simple urine or blood test to diagnose prostate cancer and monitor it without invasive biopsies.
What could go wrong
This is an early-stage study focused on collecting samples and developing methods, not yet testing a finished test. The biomarkers may not prove accurate enough in larger, diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

May 2022

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 70 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Concerning patients: 1. / Patient with suspected prostate cancer or prostatic hyperplasia with a PSA level ≥ 4 ng / ml 2. / Patient diagnosed by prostate MRI in the course of treatment 3. / No infectious episode in the week before the visit (in particular no urinary tract infection) documented by dipstick and absence of fever 4. / Information of the patient and signature of informed consent or his legal representative. 5. / Participant affiliated to a social security scheme Regarding healthy volunteers: 1. / Male from 50 to 70 years old 2. / PSA level \< 4 ng / mL 3. / No infectious episode in the week before the visit (in particular no urinary tract infection), documented by dipstick and the absence of fever 4. / Absence of cancer and history of haematological pathologies \< 5 years (in particular leukemia, lymphoma). 5. / Patient information and signature of consent Exclusion Criteria: 1 / Participants who refused to participate in the biological collection 2) Persons deprived of their liberty or under guardianship. 3) Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy donors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy donors Prostate cancer

Contacts and locations

Locations

  • Institut Curie

    Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.